A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Shandong Cancer Hospital and Institute14 sites in 1 country200 target enrollmentMarch 2015

ConditionsProsthesis Survival

Interventionsplacebo chemoradiotherapy Cisplatin Nimotuzumab radiotherapy chemoradiotherapy Paclitaxel

DrugsNimotuzumab chemoradiotherapy Paclitaxel chemoradiotherapy Cisplatin

Overview

Phase: Phase 3
Intervention: placebo
Conditions: Prosthesis Survival
Sponsor: Shandong Cancer Hospital and Institute
Enrollment: 200
Locations: 14
Primary Endpoint: Over Survival
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Esophageal cancer is the sixth leading cause of cancer death in worldwide. Over the past 2 decades, well-designed clinical trials have documented the clinical benefits of combination of chemotherapy and radiation for localized esophageal cancer, either as primary therapy or in neoadjuvant setting. Paclitaxel, a radiation sensitizer, has important single-agent activity in esophageal cancer. Paclitaxel-based chemoradiation has been the framework for the recent Radiation Therapy Oncology Group (RTOG) trials of nonoperative management of esophageal cancer. Accumulating clinical evidence suggests that Epidermal Growth Factor Receptor (EGFR) represents a viable target in the treatment of esophageal cancer. EGFR expression is associated with poor prognosis. Nimotuzumab binds specifically to EGFR on both normal and tumor cells and competitively inhibits the binding of Epidermal Growth Factor (EGF) and other ligands, such as Transforming Growth Factor-α (TGF-α). Preclinical models have suggested synergy between nimotuzumab, paclitaxel, cisplatin and radiation. For our phase II study in locally advanced esophageal squamous cell carcinoma (ESCC), the combination of cetuximab and chemoradiotherapy has demonstrated both response and survival benefits. Myara et al reported that nimotuzumab plus concurrent chemoradiation therapy (CCRT) was safe and provided statistically significant objective response (47.8%) and disease control rate (60.9%) in nonresectable ESCC. With all these, the investigators plan to study phase III trial.

Detailed Description

The primary endpoint of this study is overall survival, and the primary hypothesis is the experimental arm will improve median survival time (MST) from 18.2 month to 28.5 month. Assuming bilateral ɑ = 0.05, statistical power of 80%.Each group requires a minimum of 59 cases. Consider the 20% loss factor.The total sample size is 200 cases.It is 100 cases in each group.

Registry

clinicaltrials.gov

Start Date

March 2015

End Date

December 2021

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shandong Cancer Hospital and Institute

Responsible Party

Principal Investigator

Jinming Yu

President

Shandong Cancer Hospital and Institute

Eligibility Criteria

Inclusion Criteria

•Signed written informed consent prior to study entry
•age：18-70 years
•Histopathology confirmed primary esophageal squamous cell carcinoma, meet one of the following criteria (AJCC Staging System，2009，Seventh Edition):Cervical esophageal carcinoma(stage II-III);upper thoracic esophageal cancer or chest esophageal cancer that is unsuitable or refuse surgery (stage II-III)
•The existence of measurable lesions (according to Response Evaluation Criteria in Solid Tumors 1.1)
•Eastern Cooperative Oncology Group（ECOG）Performance status of 0-1
•Possible semi-liquid diet
•If there is a risk of pregnancy, male and female subjects must be effective contraception during treatment
•Normal bone marrow reserve: neutrophil (ANC) count≥1500/mm3,platelet count≥100,000 /mm3, hemoglobin≥5.6mmol/L(9g/dL)
•Normal renal function: serum creatinine≤1.5mg/dl and/or calculated creatinine clearance≥ 60ml/min
•Normal hepatic function: bilirubin level≤1.5×ULN, alanine aminotransferase aspartate transaminase（ASAT）\& ALST≤1.5×ULN

Exclusion Criteria

•Previous chest radiotherapy, systemic chemotherapy, and major esophageal surgery
•Concurrent chronic systemic immune therapy, targeted therapy, anti-vascular endothelial growth factor（VEGF）therapy or EGFR-pathway targeting therapy not indicated in this study protocol
•Multiple primary carcinomas of the esophagus
•Pregnancy (confirmed by urine β-HCG) or lactation period
•Uncontrolled diabetes, hypertension, and severe cardiac or pulmonary disease
•There are obvious esophageal ulcers, chest and back more than moderate pain, symptoms of esophageal perforation
•Unable to comprehend the study requirements or who are not likely to comply with the study requirements
•Patients with distant metastasis
•Patients with other malignant disease, except for curable non-melanoma skin cancer, cervical carcinoma in situ or malignant disease cure for≥5 years
•Known grade 3 or 4 allergic reaction to any of the study treatment

Arms & Interventions

placebo plus chemoradiotherapy

placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7

Intervention: placebo

Nimotuzumab plus chemoradiotherapy

Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7

Intervention: chemoradiotherapy Cisplatin